Search results for "Human papillomavirus 16"

showing 10 items of 23 documents

Linear biocompatible glyco-polyamidoamines as dual action mode virus infection inhibitors with potential as broad-spectrum microbicides for sexually …

2016

AbstractThe initial steps of viral infections are mediated by interactions between viral proteins and cellular receptors. Blocking the latter with high-affinity ligands may inhibit infection. DC-SIGN, a C-type lectin receptor expressed by immature dendritic cells and macrophages, mediates human immunodeficiency virus (HIV) infection by recognizing mannose clusters on the HIV-1 gp120 envelope glycoprotein. Mannosylated glycodendrimers act as HIV entry inhibitors thanks to their ability to block this receptor. Previously, an amphoteric, but prevailingly cationic polyamidoamine named AGMA1 proved effective as infection inhibitor for several heparan sulfate proteoglycan-dependent viruses, such …

0301 basic medicineHerpesvirus 2 HumanSexually Transmitted DiseasesMannoseBiocompatible MaterialsHIV Infections010402 general chemistrymedicine.disease_causeAntiviral Agents01 natural sciencesantivirals polymers glyco-conjugates click-chemistry HIV HPVArticleVirus03 medical and health scienceschemistry.chemical_compoundPolyaminesmedicineHumansReceptorchemistry.chemical_classificationHuman papillomavirus 16MultidisciplinarybiologyLectinHeparan sulfateVirology0104 chemical sciencesMolecular WeightMicrobicides for sexually transmitted diseases030104 developmental biologyHerpes simplex viruschemistryHIV-1biology.proteinBiological AssayGlycoproteinMannoseHeLa CellsScientific Reports
researchProduct

Inhibition of tetraspanin functions impairs human papillomavirus and cytomegalovirus infections

2018

Tetraspanins are suggested to regulate the composition of cell membrane components and control intracellular transport, which leaves them vulnerable to utilization by pathogens such as human papillomaviruses (HPV) and cytomegaloviruses (HCMV) to facilitate host cell entry and subsequent infection. In this study, by means of cellular depletion, the cluster of differentiation (CD) tetraspanins CD9, CD63, and CD151 were found to reduce HPV16 infection in HeLa cells by 50 to 80%. Moreover, we tested recombinant proteins or peptides of specific tetraspanin domains on their effect on the most oncogenic HPV type, HPV16, and HCMV. We found that the C-terminal tails of CD63 and CD151 significantly i…

0301 basic medicineHuman cytomegalovirusMaleTelomeraseTetraspaninsviruses610 MedizinCytomegalovirusIC50virus entrylcsh:ChemistryTetraspanin610 Medical scienceshuman papillomaviruslcsh:QH301-705.5SpectroscopyHuman papillomavirus 16virus diseasesGeneral MedicineBiología y Biomedicina / BiologíaEntry into hostComputer Science ApplicationsCytomegalovirus Infectionsembryonic structuresIC<sub>50</sub>HPV16BiologyCatalysisArticleInorganic Chemistry03 medical and health sciencesInhibitory Concentration 50AntigenViral entrymedicineHumansddc:610Physical and Theoretical ChemistryHumanes PapillomavirusMolecular BiologyCluster of differentiationOrganic ChemistryVirus internalizationCytomegalie-VirusIC 50Human papillomavirus virusesmedicine.diseaseVirologyHaCaT030104 developmental biologytetraspaninlcsh:Biology (General)lcsh:QD1-999human cytomegalovirusPeptidesDDC 610 / Medicine &amp; healthblocking peptideHeLa Cells
researchProduct

The Cytoskeletal Adaptor Obscurin-Like 1 Interacts with the Human Papillomavirus 16 (HPV16) Capsid Protein L2 and Is Required for HPV16 Endocytosis.

2016

ABSTRACT The human papillomavirus (HPV) capsid protein L2 is essential for viral entry. To gain a deeper understanding of the role of L2, we searched for novel cellular L2-interacting proteins. A yeast two-hybrid analysis uncovered the actin-depolymerizing factor gelsolin, the membrane glycoprotein dysadherin, the centrosomal protein 68 (Cep68), and the cytoskeletal adaptor protein obscurin-like 1 protein (OBSL1) as putative L2 binding molecules. Pseudovirus (PsV) infection assays identified OBSL1 as a host factor required for gene transduction by three oncogenic human papillomavirus types, HPV16, HPV18, and HPV31. In addition, we detected OBSL1 expression in cervical tissue sections and no…

0301 basic medicineKeratinocytesvirusesImmunologyEndocytic cycleEndocytosisMicrobiologyClathrinCell Line03 medical and health sciencesTransduction (genetics)TetraspaninViral entryVirologyTwo-Hybrid System TechniquesCaveolinHumansHuman papillomavirus 16biologyPapillomavirus InfectionsSignal transducing adaptor proteinOncogene Proteins ViralVirus InternalizationEndocytosisCell biologyVirus-Cell InteractionsCytoskeletal Proteins030104 developmental biologyInsect ScienceGene Knockdown TechniquesHost-Pathogen Interactionsbiology.proteinCapsid ProteinsHeLa CellsJournal of virology
researchProduct

DRH1 - a novel blood-based HPV tumour marker.

2020

Abstract Background To date, no studies have successfully shown that a highly specific, blood-based tumour marker to detect clinically relevant HPV-induced disease could be used for screening, monitoring therapy response or early detection of recurrence. This study aims to assess the clinical performance of a newly developed HPV16-L1 DRH1 epitope-specific serological assay. Methods In a multi-centre study sera of 1486 patients (301 Head and Neck Squamous Cell Carcinoma (HNSCC) patients, 12 HIV+ anal cancer patients, 80 HIV-positive patients, 29 Gardasil-9-vaccinees, 1064 healthy controls) were tested for human HPV16-L1 DRH1 antibodies. Analytical specificity was determined using WHO referen…

0301 basic medicineMaleResearch paperlcsh:MedicineHIV InfectionsDiseaseGastroenterologyHNSCC0302 clinical medicineNeoplasmsTumour markerMedicineProspective StudiesAged 80 and overlcsh:R5-920Human papillomavirus 16medicine.diagnostic_testbiologyGeneral MedicineMiddle AgedAnus NeoplasmsVaccinationHead and Neck Neoplasms030220 oncology & carcinogenesisArea Under CurveCarcinoma Squamous CellScreeningBiomarker (medicine)FemaleAntibodylcsh:Medicine (General)Blood testAdultHPV16medicine.medical_specialtyEarly detectionSensitivity and SpecificityGeneral Biochemistry Genetics and Molecular BiologyAntibodies03 medical and health sciencesInternal medicineBiomarkers TumorBlood testAnal cancerHumansPapillomavirus VaccinesAgedbusiness.industrylcsh:RPapillomavirus InfectionsOncogene Proteins Viralmedicine.diseaseHead and neck squamous-cell carcinoma030104 developmental biologyCross-Sectional StudiesCase-Control Studiesbiology.proteinCapsid ProteinsbusinessCarrier ProteinsEBioMedicine
researchProduct

Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).

2007

Persistent infection with human papillomaviruses (HPV) is a prerequisite for the development of cervical cancer. Vaccination with virus-like particles (VLP) has demonstrated efficacy in prophylaxis but lacks therapeutic potential. HPV16 L1E7 chimeric virus-like particles (CVLP) consist of a carboxy-terminally truncated HPV16L1 protein fused to the amino-terminal part of the HPV16 E7 protein and self-assemble by recombinant expression of the fusion protein. The CVLP are able to induce L1- and E7-specific cytotoxic T lymphocytes. We have performed a first clinical trial to gain information about the safety and to generate preliminary data on the therapeutic potential of the CVLP in humans. A …

AdultCancer ResearchTime FactorsOncogene Proteins FusionvirusesUterine Cervical NeoplasmsCervical intraepithelial neoplasiaCancer VaccinesDrug Administration ScheduleDouble-Blind MethodMedicineHumansPapillomavirus VaccinesAdverse effectAgedCervical cancerHuman papillomavirus 16biologybusiness.industryPapillomavirus Infectionsvirus diseasesOncogene Proteins ViralMiddle Agedmedicine.diseaseUterine Cervical Dysplasiafemale genital diseases and pregnancy complicationsVaccinationClinical trialTumor Virus InfectionsTreatment OutcomeOncologyImmunizationHigh Grade Cervical Intraepithelial NeoplasiaImmunologyDNA Viralbiology.proteinFemaleAntibodybusinessInternational journal of cancer
researchProduct

Peritoneal HPV‐DNA test in cervical cancer (PIONEER study): A proof of concept

2020

The aim of this study was to investigate the prevalence of peritoneal human papillomavirus (HPV) infection in different clinical cervical cancer (CC) settings, and its association with potential clinical and/or histological factors. This is a single-center, prospective, observational study. Consecutive patients with newly diagnosed or recurrent/persistent CC, between March 2019 and April 2020, were included. A group of patients undergoing surgery for benign gynecological conditions was included as control group. All patients underwent HPV-DNA test in the cervix and in the peritoneal cavity simultaneously at time of surgery. Two-hundred seventy-two patients had cervical and peritoneal HPV te…

AdultHPVCancer Researchmedicine.medical_specialtyMultivariate analysiscervical cancergenotypemedicine.medical_treatmentUterine Cervical Neoplasmsprognostic factors.GastroenterologyHuman Papillomavirus DNA Tests03 medical and health sciencesPeritoneal cavity0302 clinical medicinegenotypesInternal medicineGenotypemedicineHumansProspective StudiesStage (cooking)Peritoneal CavityCervixAgedNeoplasm StagingAged 80 and overCervical cancerHuman papillomavirus 16Human papillomavirus 18business.industryHPV infectionprognostic factorsMiddle Agedperitoneummedicine.diseaseCervical conizationinfectionSettore MED/40 - GINECOLOGIA E OSTETRICIAmedicine.anatomical_structureOncology030220 oncology & carcinogenesisFemalebusinessInternational Journal of Cancer
researchProduct

Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-lab…

2021

Abstract: Background: Efficacy of the nine-valent human papillomavirus (9vHPV; HPV types 6/11/16/18/31/33/45/52/58) vaccine was demonstrated in a phase 3 study in women 16 & ndash;26 years of age. We present a phase 3 immunogenicity and safety study of the 9vHPV vaccine in women 27 & ndash;45 versus 16 & ndash;26 years of age. Methods: This international, open-label study (NCT03158220) was conducted in women 16 & ndash;45 years of age. Participants (16 & ndash;26 years, n = 570 and 27 & ndash;45 years, n = 642) received a three-dose 9vHPV vaccination regimen (day 1, month 2, month 6). Month 7 geometric mean titers (GMTs) and seroconversion percentages to anti-HPV 6/11/16/18/31/33/45/52/58 w…

AdultHuman papillomavirusmedicine.medical_specialtyAdolescentAntibodies ViralYoung Adult03 medical and health sciencesNine-valent human papillomavirus vaccineImmunogenicity Vaccine0302 clinical medicine030225 pediatricsInternal medicinemedicineHumansPapillomavirus Vaccines030212 general & internal medicineSeroconversionHPV prophylaxisAdverse effectAgedCervical cancerHuman papillomavirus 16Human papillomavirus 18General VeterinaryGeneral Immunology and Microbiologybusiness.industryPapillomavirus InfectionsAdult vaccinationPublic Health Environmental and Occupational Healthmedicine.diseaseVaccine efficacyConfidence interval3. Good healthVaccinationClinical trialPrecancerRegimenInfectious DiseasesCervical cancerMolecular MedicineFemaleHuman medicinebusinessVaccine
researchProduct

Prevalence of herpes simplex, Epstein Barr and human papilloma viruses in oral lichen planus.

2011

Objectives: The aim of the present study was to assess the prevalence of Herpes Simplex virus, Epstein Barr virus and Human Papilloma virus -16 in oral lichen planus cases and to evaluate whether any clinical variant, histopathological or demographic feature correlates with these viruses. Study Design: The study was conducted on 65 cases. Viruses were detected immunohistochemically. We evaluated the histopathological and demographic features and statistically analysed correlation of these features with Herpes Simplex virus, Epstein Barr virus and Human Papilloma virus-16 positivity. Results: Herpes Simplex virus was positive in six (9%) cases and this was not statistically significant. The …

AdultMaleSimplexvirusHerpesvirus 4 Humanfood.ingredientvirusesmedicine.disease_causeVirusYoung Adultfoodstomatognathic systemmedicineHumansSimplexvirusskin and connective tissue diseasesGeneral DentistryPathologicalAgedHuman papillomavirus 16integumentary systembusiness.industryEpstein-Barr Virus PositiveMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Epstein–Barr virusVirologystomatognathic diseasesHerpes simplex virusCross-Sectional StudiesOtorhinolaryngologyImmunologyUNESCO::CIENCIAS MÉDICASPapillomaSurgeryOral lichen planusFemalebusinessLichen Planus OralMedicina oral, patologia oral y cirugia bucal
researchProduct

Determinants of high-grade anal intraepithelial lesions in HIV-positive MSM.

2018

Objective - To assess determinants for histologically proven high-grade anal intraepithelial lesions (hHSIL) in HIV-positive men who have sex with men (MSM), a population at high-risk of HPV-related anal cancer. Design - APACHES is a prospective study of anal HPV and related-lesions in 513 HIV-positive MSM aged at least 35 years in six centres across France. Methods - At baseline, participants underwent high-resolution anoscopy (HRA) with biopsy of suspicious lesions, preceded by anal swabs for liquid-based cytology, p16/Ki67 immunostaining, and HPV DNA. hHSIL diagnosis was established by histopathological review panel consensus, and determinants assessed by logistic regression. Results - B…

AdultMalemedicine.medical_specialtyBiopsyImmunologyPopulationHIV InfectionsMen who have sex with men03 medical and health sciences0302 clinical medicineCytologyInternal medicineBiopsymedicinePrevalenceImmunology and AllergyAnal cancerHumans030212 general & internal medicineProspective StudiesHomosexuality MaleProspective cohort studyeducationAgededucation.field_of_studyHuman papillomavirus 16medicine.diagnostic_testbusiness.industryPapillomavirus InfectionsAnoscopyMiddle Agedmedicine.diseaseAnus Neoplasms3. Good healthInfectious Diseases030220 oncology & carcinogenesisFemaleFranceSquamous Intraepithelial Lesions of the CervixbusinessAscusAIDS (London, England)
researchProduct

The endocytic trafficking pathway of oncogenic papillomaviruses

2019

Over the last two decades many host cell proteins have been described to be involved in the process of infectious entry of oncogenic human papillomaviruses (HPV). After initial binding and priming of the capsid, a sequence of events on the cell surface precedes the formation of the HPV entry platform. It has been shown that the virus-associated entry complex consists of membrane organizers, tetraspanins CD151 and CD63, and their associated partner proteins such as integrins, growth factor receptors, and the annexin A2 heterotetramer. Further recruitment of cytoplasmic factors such as the obscurin-like protein 1 and actin results in a non-canonical clathrin-independent endocytosis of the vir…

EndosomevirusesIntegrinEndocytic cycleAnnexinEndocytosisArticlelcsh:Infectious and parasitic diseasesEntry receptor complex03 medical and health sciences0302 clinical medicineTetraspaninViral entryVirologyHumansMedicinelcsh:RC109-216030212 general & internal medicineHuman papillomavirus 16Traffickingbiologybusiness.industryPapillomavirus InfectionsBiological TransportVirus InternalizationTetraspaninEndocytosisVirusCell biologyInfectious DiseasesCapsid030220 oncology & carcinogenesisHost-Pathogen Interactionsbiology.proteinbusinessAnnexin A2Papillomavirus Research
researchProduct